PL3059227T3 - Sól heterocyklicznego związku zawierającego azot lub jej kryształ, kompozycja farmaceutyczna i inhibitor flt3 - Google Patents

Sól heterocyklicznego związku zawierającego azot lub jej kryształ, kompozycja farmaceutyczna i inhibitor flt3

Info

Publication number
PL3059227T3
PL3059227T3 PL14854750T PL14854750T PL3059227T3 PL 3059227 T3 PL3059227 T3 PL 3059227T3 PL 14854750 T PL14854750 T PL 14854750T PL 14854750 T PL14854750 T PL 14854750T PL 3059227 T3 PL3059227 T3 PL 3059227T3
Authority
PL
Poland
Prior art keywords
nitrogen
salt
crystal
pharmaceutical composition
heterocyclic compound
Prior art date
Application number
PL14854750T
Other languages
English (en)
Inventor
Shinsuke Mizumoto
Takuya Matsumoto
Original Assignee
Fujifilm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Corp filed Critical Fujifilm Corp
Publication of PL3059227T3 publication Critical patent/PL3059227T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/28Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02Dicarboxylic acids
    • C07C55/10Succinic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13Dicarboxylic acids
    • C07C57/15Fumaric acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/105Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
    • C07C65/11Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL14854750T 2013-10-16 2014-10-15 Sól heterocyklicznego związku zawierającego azot lub jej kryształ, kompozycja farmaceutyczna i inhibitor flt3 PL3059227T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013215755 2013-10-16
EP14854750.8A EP3059227B1 (en) 2013-10-16 2014-10-15 Salt of nitrogen-containing heterocyclic compound or crystal thereof, pharmaceutical composition, and flt3 inhibitor
PCT/JP2014/077368 WO2015056683A1 (ja) 2013-10-16 2014-10-15 含窒素複素環化合物の塩またはその結晶、医薬組成物およびflt3阻害剤

Publications (1)

Publication Number Publication Date
PL3059227T3 true PL3059227T3 (pl) 2019-11-29

Family

ID=52828126

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14854750T PL3059227T3 (pl) 2013-10-16 2014-10-15 Sól heterocyklicznego związku zawierającego azot lub jej kryształ, kompozycja farmaceutyczna i inhibitor flt3

Country Status (13)

Country Link
US (1) US9701644B2 (pl)
EP (1) EP3059227B1 (pl)
JP (1) JP5887028B2 (pl)
KR (1) KR101744033B1 (pl)
CN (1) CN105683167B (pl)
AU (1) AU2014335312B9 (pl)
BR (1) BR112016008080B1 (pl)
CA (1) CA2927079C (pl)
DK (1) DK3059227T3 (pl)
ES (1) ES2738573T3 (pl)
PL (1) PL3059227T3 (pl)
RU (1) RU2641106C2 (pl)
WO (1) WO2015056683A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3195866B1 (en) * 2014-08-22 2020-11-18 FUJIFILM Corporation Pharmaceutical composition for treating flt3 mutation-positive cancer, mutant flt3 inhibitor and uses thereof
US11286670B2 (en) 2015-02-06 2022-03-29 Roofguard Manufacturing, Llc Roof drain cover
JP6412471B2 (ja) * 2015-07-15 2018-10-24 富士フイルム株式会社 含窒素複素環化合物の製造方法およびその中間体
TW202027749A (zh) 2018-10-12 2020-08-01 日商富士軟片股份有限公司 急性骨髓性白血病用抗腫瘤劑
EP3875088A4 (en) * 2018-10-31 2021-12-29 FUJIFILM Corporation Package for medical composition containing anti-tumor agent
EP3875089A4 (en) * 2018-10-31 2021-12-22 FUJIFILM Corporation TABLET CONTAINING AN ANTI-TUMOR AGENT
EP3875090A4 (en) * 2018-10-31 2021-12-22 FUJIFILM Corporation PELLET CONTAINING AN ANTITUMOR AGENT
EP3875091A4 (en) * 2018-10-31 2021-12-29 FUJIFILM Corporation Pharmaceutical composition containing antitumor agent
TW202045174A (zh) 2019-02-28 2020-12-16 日商富士軟片股份有限公司 組合醫藥
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
MX2024008057A (es) 2021-12-30 2024-08-28 Biomea Fusion Inc Compuestos de pirazina como inhibidores de flt3.
WO2023225005A1 (en) 2022-05-17 2023-11-23 Biomea Fusion, Inc. Flt3 combination therapy for cancer and compositions therefor

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8928839D0 (en) 1989-12-21 1990-02-28 Beecham Group Plc Novel compounds
US5936399A (en) * 1997-09-16 1999-08-10 Mitutoyo Corporation Inductive position transducer having a multi-tap receiver winding
ATE407678T1 (de) * 2001-10-17 2008-09-15 Boehringer Ingelheim Pharma Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
BRPI0610876B8 (pt) * 2005-06-08 2021-05-25 Rigel Pharmaceuticals Inc composto, formulação farmacêutica, e métodos de inibir uma atividade de uma jak cinase, e de inibir uma cascata de transdução de sinal em que jak3 cinase desempenha um papel
CN101282945A (zh) * 2005-06-08 2008-10-08 里格尔药品股份有限公司 抑制jak途径的组合物和方法
US8071768B2 (en) * 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
US20060281755A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
US7825244B2 (en) * 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
JP5688877B2 (ja) 2005-11-11 2015-03-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌疾患の治療用キナゾリン誘導体
KR101449057B1 (ko) 2006-03-17 2014-10-10 암비트 바이오사이언시즈 코포레이션 질환 치료용 이미다졸로티아졸 화합물
EP2022785A1 (en) * 2007-06-20 2009-02-11 Bayer Schering Pharma Aktiengesellschaft Alkynylpyrimidines as Tie2 kinase inhibitors
KR20100050471A (ko) * 2007-06-21 2010-05-13 샌디스크 코포레이션 프로그램 펄스 지속 시간의 지능적 제어
MX2010007973A (es) 2008-02-01 2010-11-09 Akinion Pharmaceuticals Ab Derivados de pirazina y su uso como inhibidores de proteina cinasa.
MX353308B (es) 2008-05-21 2018-01-08 Ariad Pharma Inc Derivados fosforosos como inhibidores de cinasa.
US9908884B2 (en) * 2009-05-05 2018-03-06 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and methods of treating disorders
US9290485B2 (en) * 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
WO2012061303A1 (en) 2010-11-01 2012-05-10 Avila Therapeutics, Inc. Heteroaryl compounds and uses thereof
WO2012064706A1 (en) 2010-11-10 2012-05-18 Avila Therapeutics, Inc. Mutant-selective egfr inhibitors and uses thereof
JP6147727B2 (ja) 2011-04-01 2017-06-14 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション チロシン受容体キナーゼbtk阻害剤としての置換n−(3−(ピリミジン−4−イル)フェニル)アクリルアミド類似体
RU2616612C2 (ru) 2011-05-04 2017-04-18 ФОРМА ТиЭм, ЭлЭлСИ Новые соединения и композиции для ингибирования nampt
HRP20180037T1 (hr) * 2012-04-17 2018-03-23 Fujifilm Corporation Heterociklični spoj koji sadrži dušik ili njegovu sol

Also Published As

Publication number Publication date
KR101744033B1 (ko) 2017-06-07
HK1219946A1 (zh) 2017-04-21
EP3059227A1 (en) 2016-08-24
US20160229812A1 (en) 2016-08-11
BR112016008080B1 (pt) 2021-02-23
AU2014335312A1 (en) 2016-05-05
CA2927079C (en) 2017-05-23
US9701644B2 (en) 2017-07-11
EP3059227A4 (en) 2016-09-07
JP5887028B2 (ja) 2016-03-16
JPWO2015056683A1 (ja) 2017-03-09
ES2738573T3 (es) 2020-01-23
EP3059227B1 (en) 2019-06-26
AU2014335312B9 (en) 2017-05-25
AU2014335312B2 (en) 2017-01-05
CN105683167B (zh) 2018-10-23
DK3059227T3 (da) 2019-08-26
WO2015056683A1 (ja) 2015-04-23
RU2016114540A (ru) 2017-11-21
BR112016008080A8 (pt) 2020-03-17
CN105683167A (zh) 2016-06-15
KR20160049009A (ko) 2016-05-04
RU2641106C2 (ru) 2018-01-16
CA2927079A1 (en) 2015-04-23

Similar Documents

Publication Publication Date Title
PL3059227T3 (pl) Sól heterocyklicznego związku zawierającego azot lub jej kryształ, kompozycja farmaceutyczna i inhibitor flt3
IL267090A (en) Amine-disubstituted heterocyclic compounds as ehmt2 inhibitors and methods of using them
IL256500A (en) Heterocyclic amides as kinase inhibitors
ZA201408397B (en) Nitrogen-containing heterocyclic compound or salt thereof
DK2947084T3 (da) Fem- og seks-ledet heterocyklisk forbindelse og forberedelsesmetode, farmaceutisk sammensætning og anvendelse deraf
IL253538A0 (en) Heterocyclic compound and pharmaceutical compound containing it
IL244268A0 (en) Heterocyclic compounds and methods of use
EP3019477A4 (en) Heterocyclic compounds and methods of their use
SG10201912293UA (en) Stable crystal form of tipiracil hydrochloride and crystallization method for the same
EP2961403A4 (en) HETEROCYCLIC INHIBITORS OF SODIUM CHANNEL
IL240875A0 (en) Heterocyclic compounds and pharmaceutical preparations containing them
PT3202772T (pt) Cristal de um complexo de l-prolina/inibidor do cotransportador de sódio-glicose 2